as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. The company also offers laboratory services that apply immunofluorescence and intraepidermal nerve fibre density assessment to support clinical decision-making in neurodegenerative and autonomic disorders. In addition, it collaborates with biopharmaceutical organisations to support clinical trials through biomarker services and longitudinal assessment of nerve-based pathology.